← All indications
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Drugs by status
Approved for this indication (17)
Phase 4 trials (24)
- cytarabine
- teniposide
- valganciclovir
- pentostatin
- urea
- cladribine
- tioguanine
- idarubicin
- doxorubicin
- sargramostim
- 23-valent pneumococcal polysaccharide vaccine
- asparaginase
- pirtobrutinib
- pneumococcal 13-valent conjugate vaccine
- naltrexone
- ifosfamide
- daunorubicin
- stem cells
- cyclophosphamide
- mercaptopurine
- etoposide
- mitoxantrone
- prednisone
- vincristine
Phase 3 trials (42)
- calcium phosphate
- clofarabine
- hyaluronidase (human recombinant)
- dasatinib
- pegaspargase
- bgb-11417
- umbralisib
- allopurinol
- blinatumomab
- leucovorin
- immune globulin (human)
- autologous hematopoietic stem cells
- bnt162b2
- calaspargase pegol
- darbepoetin alfa
- dzd8586
- levocarnitine
- lisocabtagene maraleucel
- lenalidomide
- cyclosporine
- allogeneic hematopoietic stem cells
- Filgrastim
- COVID-19 Vaccine, Adjuvanted
- ublituximab
- mrna-1273
- mycophenolate
- cd19 car-t cells
- arsenic trioxide
- tacrolimus
- darbepoetin beta
- +12 more
Phase 2 trials (287)
- omacetaxine
- ciprofloxacin
- dtrm-555
- busulfan
- iov-2001
- glofitamab
- cerdulatinib
- otlertuzumab
- invac-1
- dacetuzumab
- valaciclovir
- paclitaxel
- allogeneic cord blood
- parsaclisib
- rp-3500
- aeg35156
- navtemadlin
- imatinib
- gemcitabine
- icosapent ethyl
- nicotinamide
- t lymphocytes
- autologous lymphocytes
- cd3/cd28 stimulated t cells
- m7583
- urokinase-derived peptide a6
- mirdametinib
- allogeneic stem cells
- car-t targeted cd19/cd20/cd22/cd30
- veliparib
- +257 more
Phase 1 trials (238)
- pertuzumab
- ly3214996
- voruciclib
- bgb-21447
- anti-cd19 and anti-cd20 bicistronic car t- cells
- myeloid progenitor cells
- gdc-0853
- linperlisib
- ms-533
- cd19 car-nk cells
- acp-319
- sjg-136
- telisotuzumab vedodin
- chimeric antigen receptor t cells, eps8 or wt1 peptide specific dendritic cell
- 7-hydroxystaurosporine
- pf-00258210
- as-1763
- becatecarin
- cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
- PSB107
- autologous ebv specific cytotoxic t lymphocytes
- ulocuplumab
- jnj-67856633
- hla-mismatched stem cell
- vemurafenib
- jnj-64619178
- ciclopirox
- prgn-3007
- levoleucovorin
- cd40 ligand and il-2-expressing tumor cells vaccine
- +208 more
Organizations
Organization Involved with Phase 4 Indications (10)
Organization Involved with Phase 3 Indications (77)
- Napo Pharmaceuticals
- Celgene
- Genta
- AstraZeneca
- Octapharma
- Biogen
- Novartis
- BeOne Medicines
- Chugai
- Hikma
- Mundipharma
- Parexel
- Shandong Lanjin Pharmaceuticals Co.,Ltd
- Sponsor GmbH
- TG Therapeutics, Inc.
- PETHEMA Foundation
- National Institutes of Health (NIH)
- Medical Research Council
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Cancer and Leukemia Group B (CALGB)
- Case Western Reserve University
- Cancer Trials Ireland
- Centre Henri Becquerel
- Cornell University
- Dartmouth University
- Eastern Cooperative Oncology Group
- ECOG-ACRIN Cancer Research Group
- German CLL Study Group
- +47 more
Organization Involved with Phase 2 Indications (269)
- Pierre Fabre
- Zhejiang DTRM Biopharma
- Incyte
- Abbott
- Ligand Pharmaceuticals
- Spectrum Pharmaceuticals
- Seattle Genetics
- Eisai
- MorphoSys
- Spirogen
- Aptevo Therapeutics
- Bristol-Myers Squibb
- BioCryst
- Amgen
- Emergent BioSolutions
- OSI Pharmaceuticals
- Advancell - Advanced In Vitro Cell Technologies, S.A.
- Astellas
- Immunomedics
- Schering-Plough
- Titan Pharmaceuticals
- Aegera Therapeutics
- Schering AG
- MedImmune
- Pfizer
- Sanofi
- Alexion
- Aprea Therapeutics AB
- Asana BioSciences
- Ascenta Therapeutics
- +239 more
Organization Involved with Phase 1 Indications (104)
- ADC Therapeutics SARL
- Swedish Orphan Biovitrum
- Acetylon Pharmaceuticals Incorporated
- Regeneron
- Intrexon
- Daiichi Sankyo
- Corixa
- Cambridge Antibody Technology
- Takeda
- Medarex
- Servier
- Morphotek
- Medivation
- Eli Lilly
- Exelixis
- Merck KGaA
- Aptose Biosciences Inc.
- Arno Therapeutics
- ArQule
- Bio-Path Holdings, Inc.
- CARsgen Therapeutics, Ltd.
- Erimos Pharmaceuticals
- Fate Therapeutics
- Infinity Pharmaceuticals, Inc.
- Karyopharm Therapeutics Inc
- Kyowa Hakko Kirin
- Laboratoire français de Fractionnement et de Biotechnologies
- LAM Therapeutics Inc.
- MingSight Pharmaceuticals Pty Limited
- Oncovir, Inc.
- +74 more
Organization Involved with Other Experimental Indications (8)